Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | LDHA | P00338 | 1/20 | 0.30 |
| ▸ | LDHB | P07195 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2132672 | 0.85 | UCHL1 (0.37) | UCHL1SLC6A3L3MBTL1AAK1ESR1 | |
| SCHEMBL2128253 | 0.79 | MT-CO2 (0.40) | UCHL1SLC6A3L3MBTL1AAK1SLC6A2 | |
| SCHEMBL631558 | 0.72 | SLC6A3 (0.50) | SLC6A3L3MBTL1SLC6A2SLC6A4 | |
| SCHEMBL4468874 | 0.69 | ALDH1A1 (0.44) | UCHL1L3MBTL1 | |
| SCHEMBL2646900 | 0.69 | SLC6A3 (0.49) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL29734873 | 0.69 | ALDH1A1 (0.44) | UCHL1L3MBTL1 | |
| SCHEMBL2131624 | 0.69 | ALDH1A1 (0.43) | UCHL1L3MBTL1 | |
| SCHEMBL30019267 | 0.69 | ALDH1A1 (0.43) | UCHL1L3MBTL1 | |
| SCHEMBL18300674 | 0.68 | KMT2A (0.51) | ESR1ESR2 | |
| SCHEMBL10650293 | 0.68 | SLC6A3 (0.48) | SLC6A3L3MBTL1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289520-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2012-11-15 | — | — | US | disclosed |
| US-20120289520-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2012-11-15 | — | — | US | disclosed |
| US-20120289520-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2012-11-15 | — | — | US | disclosed |
| US-8188092-B2 | Substituted pyrazines as DGAT-1 inhibitors | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| US-8188092-B2 | Substituted pyrazines as DGAT-1 inhibitors | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| US-8188092-B2 | Substituted pyrazines as DGAT-1 inhibitors | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| EP-2443096-A1 | PYRAZINE CARBOXAMIDES AS INHIBITORS OF DGAT1 | AstraZeneca AB (SE) | 2012-04-25 | — | — | EP | disclosed |
| US-20100324068-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324068-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324068-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | US | disclosed |
| WO-2010146395-A1 | PYRAZINE CARBOXAMIDES AS INHIBITORS OF DGAT1 | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010146395-A1 | PYRAZINE CARBOXAMIDES AS INHIBITORS OF DGAT1 | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324068-A1 | CHEMICAL COMPOUNDS 785 | GPBAR1, DGAT1, GPR119 | UCHL1 3564/4885SLC6A3 410/4885L3MBTL1 1548/4885 |
| US-20120289520-A1 | CHEMICAL COMPOUNDS 785 | DGAT1, DGAT2, SLC5A1 | UCHL1 3452/4885SLC6A3 318/4885L3MBTL1 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.